The FDA has expanded Wegovy use to include adults with metabolic-associated steatohepatitis (MASH) and moderate to severe fibrosis, or scarring in the liver. AACE President Scott D. Isaacs, MD, FACP, FACE, explained that semaglutide acts on the brain’s appetite regulation center to decrease appetite and reduce cravings, leading to significant, sustained weight loss that in turn improves insulin sensitivity, decreases liver fat, and can reverse the inflammation and cellular injury in MASH. Learn more by reading the full article on Everyday Health.